Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Article in English | WPRIM | ID: wpr-1044989

ABSTRACT

Background@#Wistar rats are extensively used as the model for assessing toxicity and efficacy in preclinical research.Hematological and biochemical laboratory data are essential for evaluating specific variations in the physiological and functional profile of a laboratory animal. Establishing hematological and biochemical reference values for Wistar (han) rats at various age intervals was the goal of this work. Male and female Wistar rats (n = 660) of ages 6–8 weeks, 10–14 weeks and > 6 months were used in the experiment. Blood and serum were collected from these rats under fasting conditions. @*Results@#We observed that the majority of hematological and biochemical parameters were significantly influenced by sex and age. Hematological changes were significantly correlated to aging were increased red blood cells, hemoglobin, hematocrit, neutrophils, monocytes and eosinophils in both sexes, as well as decreased platelet, mean corpuscular volume, mean corpuscular hemoglobin and lymphocytes in both sexes. White blood cells of male rats were considerably higher than those of female rats in all age ranges. For biochemistry, increase in glucose, total protein and creatinine were seen in both sexes, along with increases in urea in females and alanine aminotransferase in males.Age was significantly associated with decreased alkaline phosphatase in both sexes. @*Conclusions@#When using Wistar rats as a model, these reference values may be useful in evaluating the results.

2.
Ann. hepatol ; Ann. hepatol;16(1): 133-139, Jan.-Feb. 2017. graf
Article in English | LILACS | ID: biblio-838095

ABSTRACT

Abstract: Introduction and aims. Cholangiocarcinomas are a heterogeneous group of tumors that can be classified into three clinically distinct types of cancers, intrahepatic, perihilar and distal cholangiocarcinoma. The inconsistent use of nomenclature for these cancers has obscured a true knowledge of the epidemiology, natural history and response to therapy of these cancers. Our aims were to define demographic characteristics, management and outcomes of these three distinct cancer types. Materials and methods. A retrospective study of patients enrolled in an institutional cancer registry from 1992 to 2010. Median survival was compared between different treatment modalities over three time periods for the three types of cholangiocarcinoma at different stages of the disease using Kaplan Meyer analysis. Results. 242 patients were identified. All cases were reviewed and classified into intrahepatic (90 patients), distal (48 patients) or perihilar (104 patients) cholangiocarcinomas. These cancers differed in median age of onset, gender distribution, median survival and stage. 13.8% of patients presented with stage I, 5.8% with stage II, 9.6% with stage III, 28% with stage IV, with 41.8% having unknown stage. The overall median survival was 15.8 months, and was 23, 25, 14, and 4.5 months for stages I, II, III, and IV respectively. Surgery improved survival in both early and advanced stages. Multimodality therapies further improved outcomes, particularly for perihilar cholangiocarcinoma. Conclusion. Perihilar, distal and intrahepatic cholangiocarcinoma vary in their presentation, natural history and therapeutic approach to management. A consistently applied classification is essential for meaningful interpretation of studies of these cancers.


Subject(s)
Humans , Middle Aged , Aged , Bile Duct Neoplasms/therapy , Biliary Tract Surgical Procedures , Cholangiocarcinoma/therapy , Antineoplastic Agents/therapeutic use , Time Factors , Bile Duct Neoplasms/classification , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/pathology , Biliary Tract Surgical Procedures/adverse effects , Biliary Tract Surgical Procedures/mortality , Registries , Florida , Retrospective Studies , Treatment Outcome , Chemotherapy, Adjuvant , Klatskin Tumor/classification , Klatskin Tumor/mortality , Klatskin Tumor/pathology , Klatskin Tumor/therapy , Cholangiocarcinoma/classification , Cholangiocarcinoma/mortality , Cholangiocarcinoma/pathology , Radiotherapy, Adjuvant , Kaplan-Meier Estimate , Neoplasm Staging , Antineoplastic Agents/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL